Completado

The Dose-response Effects of D-allulose (Psicose) With Sucrose Beverage on Glucose Tolerance and Insulin Level in Healthy Volunteers and Volunteers With Impaired Fasting Glucose

0 criterios cumplidosConsulta de un vistazo cómo tu perfil cumple con cada criterio de elegibilidad.
Qué se está evaluando

D-allulose

Suplemento Dietético
Quiénes están siendo reclutados

Hiperglucemia

+ Enfermedades metabólicas

+ Enfermedades Nutricionales y Metabólicas

De 18 a 85 años
+15 Criterios de eligibilidad
Ver todos los criterios de elegibilidad
Cómo está diseñado el estudio

Estudio de Prevención

Controlado con Placebo
Intervencional
Inicio del estudio: abril de 2015
Ver detalles del protocolo

Resumen

Patrocinador PrincipalChiang Mai University
Última actualización: 27 de enero de 2026
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Fecha de inicio: 1 de abril de 2015

Fecha en la que se inscribió al primer participante.

Objectives Primary objectives 1. To investigate the dose-response effects of D-allulose (psicose) with sucrose beverage on glucose tolerance 2. To investigate the dose-response effects of D-allulose (psicose) with sucrose beverage on insulin levels Subjects and methods Study product A. Sucrose 50 g B. Sucrose 50 g + D-allulose (psicose) 2.5 g C. Sucrose 50 g + D-allulose (psicose) 5 g D. Sucrose 50 g + D-allulose (psicose) 7.5 g E. Sucrose 50 g + D-allulose (psicose) 10 g Study plan Screening (visit 0) * Obtain inform consent * History taking for medical problems, smoking, alcoholic drinking, concurrent medication, contraception or menopausal status, weight history * Measure body weight, height and calculated BMI * Measure waist and hip circumference * Body composition measurement by bioelectrical impedance analysis (BIA) * Complete physical examination * Urine pregnancy test in all female of childbearing potential * Provide 24-hour food record * Ask to come back within 1 week Visit 1: (day 7 or 6-11 days) * Complete physical examination * Randomize subject to receive any 1 of 5 study products * Perform OSTT with that product * Return food record * Provide 24-hour food record * Adverse events evaluation * Ask to come back within 7 +/- 4 days Visit 2: (day 7 or 6-11 days from visit 1) * Complete physical examination * Randomize subject to receive any 1 of 4 study product which are left * Perform OSTT with that product * Return food record * Provide 24-hour food record * Adverse events evaluation * Ask to come back within 7 +/- 4 days Visit 3 (day 7 or 6-11 days from visit 2) * Complete physical examination * Randomize subject to receive any 1 of 3 study product which are left * Perform OSTT with that product * Return food record * Provide 24-hour food record * Adverse events evaluation * Ask to come back within 7 +/- 4 days Visit 4 (day 7 or 6-11 days from visit 3) * Complete physical examination * Randomize subject to receive any 1 of 2 study product which are left * Perform OSTT with that product * Return food record * Provide 24-hour food record * Adverse events evaluation * Ask to come back within 7 +/- 4 days Visit 5 (day 7 or 6-11 days from visit 4) * Complete physical examination * Perform OSTT with the product that is left * Return food record * Adverse events evaluation Adverse Event Assessment At each visit, participants will be asked an open question as if he/she has experienced any abnormal symptoms. Any symptom reported by the participants will be recorded as an adverse events with details of the event, its severity, start and stop dates, and relationship to study products. Gastrointestinal symptoms (heartburn, distension, nausea, vomiting, abdominal pain, flatulence, constipation and diarrhea) within 24 hours after OSTT will be asked and recorded as well. Withdrawal criteria 1. Those who are not able to complete 5 visits of OSTT within 8 weeks 2. Those who cannot provide 24-hour dietary record at each visit 3. Those who start any medication that might cause increasing in plasma glucose during participating in the study

Título OficialThe Dose-response Effects of D-allulose (Psicose) With Sucrose Beverage on Glucose Tolerance and Insulin Level in Healthy Volunteers and Volunteers With Impaired Fasting Glucose
NCT02455934
Patrocinador PrincipalChiang Mai University
Última actualización: 27 de enero de 2026
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Protocolo

Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.
Detalles del Diseño

Se reclutarán 30 pacientes

Número total de participantes que el ensayo clínico espera reclutar.

Estudio de Prevención

Los estudios de prevención buscan evitar que se desarrolle una enfermedad. A menudo incluyen a personas en riesgo y evalúan vacunas, cambios en el estilo de vida o medicamentos preventivos.



Elegibilidad

Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.
Condiciones
Criterios

Cualquier sexo

Sexo biológico de los participantes elegibles para inscribirse.

De 18 a 85 años

Rango de edades de los participantes que pueden unirse al estudio.

Voluntarios sanos permitidos

Indica si personas sanas, sin la condición que se estudia, pueden participar.

Condiciones

Patología

HiperglucemiaEnfermedades metabólicasEnfermedades Nutricionales y Metabólicas

Criterios

5 criterios de inclusión requeridos para participar
Male or female, age > 18 years and legal age of consent.

If female, the participant is either post-menopausal or surgically sterilized, or has a negative urine kit pregnancy test within 7 days prior to enrollment and will use adequate contraception during the study.

The participant has provided written informed consent prior to admission to the study.

Participant is able to join the entire study with 8 weeks.

Mostrar Más Criterios

10 criterios de exclusión impiden participar
Pregnancy or lactation

Diagnosed with diabetes mellitus

Those who take any medication that might be able to increase plasma glucose 1 month prior to the study or during in the study

Acute illness within 1 weeks prior to the study

Mostrar Más Criterios

Plan de Estudio

Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.
Grupos de Tratamiento
Objetivos del Estudio

5 grupos de intervención están designados en este estudio

20% de probabilidad de ser asignado al grupo placebo

Grupos de Tratamiento

Grupo I

Comparador Activo
Sucrose 50 g + D-allulose (psicose) 2.5 g

Grupo II

Comparador Activo
Sucrose 50 g + D-allulose (psicose) 10 g

Grupo III

Comparador Activo
Sucrose 50 g + D-allulose (psicose) 5 g

Grupo IV

Comparador Activo
Sucrose 50 g + D-allulose (psicose) 7.5 g

Grupo 5

Placebo
Sucrose 50 g

Objetivos del Estudio

Objetivos Primarios

Objetivos Secundarios

Centros del Estudio

Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.

Este estudio tiene una ubicación

Suspendido

Clinical trial Unit, Faculty of Medicine, Chiang Mai University

Muang, ThailandAbrir Clinical trial Unit, Faculty of Medicine, Chiang Mai University en Google Maps
Completado1 Centros de Estudio